In the January JAMA Neurology, researchers formally published the results of the Phase 3 trial of Dimebon®, aka latrepirdine, in Huntington’s disease patients. In April 2011, the drug’s sponsors, Medivation Inc. and Pfizer, announced that Dimebon failed to show efficacy in the six-month HORIZON trial, which enrolled 403 people with Huntington’s disease in 11 countries (see ARF related news story). The drug had shown hints of cognitive benefit in a Phase 2 trial (see ARF related news story), but in Phase 3, people taking Dimebon showed no improvement over controls on the Mini-Mental State Examination or the Clinician Interview-Based Impression of Change. The Huntington Study Group and the European Huntington’s Disease Network carried out the trial.

The findings echo Dimebon's tribulations in Alzheimer’s disease, where promising Phase 2 results (see ARF related news story) evaporated in Phase 3 (see ARF related news story; ARF news story).––Madolyn Bowman Rogers.

Reference:
HORIZON Investigators of the Huntington Study Group and European Huntington’s Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. Arch Neurol. 2012 Oct 1:1-9. Abstract

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

References

News Citations

  1. No Effect Seen in Huntington’s Disease Trial of Dimebon
  2. Dimebon for HD—A Hint of Cognitive Benefit?
  3. Boston: Clinical Trial Results for Dimebon Unveiled
  4. Dimebon Disappoints in Phase 3 Trial
  5. CONCERT Trial of Dimebon Falls Flat

Paper Citations

  1. A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease. Arch Neurol. 2012 Oct 1;:1-9. PubMed.

External Citations

  1. HORIZON trial
  2. Phase 2 trial

Further Reading